New drug combinations to treat newly diagnosed marginal zone lymphoma

Plain-English translation of NCT07208981 on ClinicalTrials.gov ↗ · Source last updated October 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether combined with and works better than a standard treatment combination (bendamustine with rituximab) for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. The study will enroll about 169 people across multiple hospitals and compare how well these two treatment approaches work and how safe they are.

Marginal zone lymphoma is a type of blood cancer that currently has limited treatment options, especially for newly diagnosed patients. Researchers want to see if this new medication combination can help more patients go into remission and potentially have better long-term outcomes than existing treatments.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with marginal zone lymphoma (including MALT, SMZL, or NMZL subtypes) confirmed by a biopsy
you have measurable disease that can be tracked on imaging or blood tests
your doctor believes you need treatment now based on how advanced your disease is or your symptoms
you have not received any systemic chemotherapy or targeted therapy before (though you may have had local treatments like surgery or radiation)
your overall health and organ function are adequate enough to tolerate these medications, as shown by blood tests

You likely don't qualify if…

you have been diagnosed with another type of cancer within the past 5 years (unless it was completely removed and has not come back)
your blood cell counts are too low or your liver and kidney function is too impaired to safely receive these medications
you have a blood clotting disorder or are taking blood thinners that cannot be managed safely
you are pregnant, breastfeeding, or unwilling to use effective birth control during the trial

What participation looks like

You will be assigned to receive one of two medication combinations as your treatment for marginal zone lymphoma. Depending on which group you join, you will take your assigned medications on a regular schedule (typically daily pills or periodic infusions). You will need to visit the hospital or clinic regularly for blood tests, physical exams, and imaging scans to see how well the treatment is working and to monitor for any side effects. The trial will track your health and disease response over time to compare which treatment works better.

AI-generated summary from trial data · Jun 15, 2026 · Not medical advice

Trial locations(1 site)

China

The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu